AZD6738 Plus Durvalumab in Biliary Tract Cancer

Sponsor
Seoul National University Hospital
Study ID
NCT04298008
Phase
PHASE2
Status
Unknown

Conditions

  • Bile Duct Cancer
  • Chemotherapy Effect

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AZD6738 — DRUG
    AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
  • Durvalumab — DRUG
    Durvalumab 1500 mg iv on D1 Every 4 weeks

Study Details

This trial will enroll advanced biliary tract cancer patients who have been previously treated with immunotherapy in either the 2nd or 3rd line. Patients will be treated with AZD6738 and Durvalumab combination.

Key Dates

Start date
Jun 25, 2020
Status verified
Apr 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2025

Study Design

Enrollment
26 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: AZD6738 + Durvalumab Cohort
    This is a study enrolling advanced BTC patients who have been previously treated with immunotherapy, to explore the combination of AZD6738+durvalumab

Primary Outcome Measure

disease control rate (DCR) of AZD6738 and Durvalumab combination [ Time Frame: through study completion, an average of 1 year ]

Related Studies